Phase I study to assess the histologic effect and safety of pre-operative and post-operative infusions of IL13-PE38QQR [cintredekin besudotox] cytotoxin in patients with recurrent resectable supratentorial malignant glioma.
Phase of Trial: Phase I
Latest Information Update: 02 May 2014
At a glance
- Drugs Cintredekin besudotox (Primary)
- Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma
- Focus Adverse reactions
- Sponsors INSYS Therapeutics, Inc
- 31 Aug 2018 Biomarkers information updated
- 03 Jun 2011 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
- 03 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.